Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study is an open-label extension study in Alzheimer's patients who have completed
participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN
(NCT00904683).